MD

Pediatrix Medical Group, Inc. - 2002 Annual Report (10-K) Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2002. Pediatrix Medical Group, Inc. is the nation's largest physician group focused on maternal-fetal-newborn medicine. The company employs 622 physicians, including over 500 neonatologists, staffing more than 200 hospital-based Neonatal Intensive Care Units (NICUs) across 30 states and Puerto Rico. The company's model involves contracting with hospitals to manage clinical care, billing, and administrative functions for NICUs and Maternal-Fetal Medicine (MFM) practices.

Key Financial Metrics (Year Ended Dec 31, 2002)

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 31.3% to $465.5 million. Approximately $69.8 million (62.9%) was attributable to new units from acquisitions, while same-unit revenue grew 15.6% due to price increases, improved collection rates, and higher patient volume.
• Profitability Surge: Net income more than doubled to $68.8 million. Operating income increased 91.8% to $112.1 million.
• Accounting Impact: The adoption of FAS 142 eliminated goodwill amortization, which significantly boosted reported net income and operating margins compared to 2001. Excluding goodwill amortization, 2001 pro forma net income would have been $44.4 million.
• Expense Management: General and administrative expenses as a percentage of revenue declined from 17.7% to 14.7%, contributing to margin expansion. Depreciation and amortization dropped 71.4% due to the cessation of goodwill amortization.
• Capital Allocation: The company repurchased approximately 1.7 million shares of common stock for $50 million in 2002. Cash flow from operations increased to $97.8 million.

Guidance, Outlook, Risks, and Contingencies

• Strategic Outlook: Management intends to continue growth through acquisitions of physician practices and same-unit growth by expanding services within existing hospitals. They aim to develop regional networks to improve clinical and operating efficiencies.
• Regulatory Investigations:
  • FTC Investigation: The Federal Trade Commission is investigating competition issues related to the 2001 acquisition of Magella Healthcare Corporation. The company received a subpoena in February 2003 and is cooperating, though the outcome is unpredictable.
  • Billing Audits: An ongoing TRICARE investigation regarding billing practices remains active. Previous Medicaid investigations in Arizona, Florida, and Colorado were settled. The company anticipates continued audits and inquiries.
• Legal Settlements: A class-action securities lawsuit was settled in May 2002 for $12.0 million, fully covered by insurance.
• Key Risks:
  • Reimbursement Rates: Approximately 23% of revenue comes from government programs (Medicaid). Reductions in reimbursement rates or retroactive adjustments could materially impact results.
  • Geographic Concentration: 62% of revenue is generated in the five largest states, with Texas alone accounting for 33%.
  • Insurance Costs: Professional liability insurance premiums are expected to increase, and coverage renewal terms are uncertain.

Investor Verification Checklist

• FTC Investigation Status: Verify the current status and potential financial impact of the FTC antitrust investigation regarding the Magella acquisition.
• Reimbursement Trends: Monitor changes in Medicaid and managed care reimbursement rates, particularly in Texas, which represents a significant portion of revenue.
• Goodwill Impairment: Assess the company's annual goodwill impairment testing results, as a significant write-down could reverse recent earnings gains.
• Acquisition Integration: Review the financial performance of the six practices acquired in 2002 to ensure they are meeting projected growth targets.
• Insurance Renewal: Confirm the terms and cost of the professional liability insurance policy renewal due in May 2003.